TEVA-TOPISONE OINTMENT
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
24-02-2021
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
BETAMETHASONE (BETAMETHASONE DIPROPIONATE)
Tillgänglig från:
TEVA CANADA LIMITED
ATC-kod:
D07AC01
INN (International namn):
BETAMETHASONE
Dos:
0.05%
Läkemedelsform:
OINTMENT
Sammansättning:
BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%
Administreringssätt:
TOPICAL
Enheter i paketet:
15/50/450G
Receptbelagda typ:
Prescription
Terapiområde:
ANTI-INFLAMMATORY AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0106299002; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2002-03-08
Produktens egenskaper
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-TOPISONE
BETAMETHASONE DIPROPIONATE
USP
0.05% W/W BETAMETHASONE (AS DIPROPIONATE) CREAM, OINTMENT AND LOTION
TOPICAL CORTICOSTEROID
TEVA CANADA LIMITED
DATE OF REVISION
30 NOVOPHARM COURT
FEB.24, 2021
TORONTO, ONTARIO
CANADA M1B 2K9
WWW.TEVACANADA.COM
CONTROL #: 245679
Page 2
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
1.
INDICATIONS
......................................................................................................
3
1.1 PEDIATRICS
.........................................................................................................
3
1.2 GERIATRICS
.........................................................................................................
3
2.
CONTRAINDICATIONS
........................................................................................
4
3.
DOSAGE AND ADMINISTRATION
......................................................................
4
3.1 DOSING CONSIDERATIONS
....................................................................................
4
3.2 ADMINISTRATION
..................................................................................................
4
4.
MISSED DOSE
.....................................................................................................
4
5.
OVERDOSAGE
.....................................................................................................
5
6.
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............. 5
7.
WARNINGS AND PRECAUTIONS
.......................................................................
6
7.1 SPECIAL POPULATIONS
.........................................................................................
7
7.1.1 PREGNANT WOMEN
...........................................................................................
7
7.1.2 BREAST-FEEDING
...............................................................................................
7
7.1.3 PEDIATRICS
.
Läs hela dokumentet
